ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 For Immediate Release PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that…
ImmuCell Announces Unaudited Financial Results for
the Quarter Ended June 30, 2026
For Immediate Release
PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), an animal health biologics company that develops,
manufactures and markets products to improve calf health and productivity, today announced its
unaudited financial results for the quarter ended June 30, 2026.
Management’s Discussion:
“Today we are reporting net income of $1.8 million for the second quarter of 2026,” commented
Timothy C. Fiori, Chief Financial Officer of ImmuCell. “Revenue grew 11.5% to $7.2 million in
the second quarter of 2026, which is a strong positive market signal in the face of high revenue
in the second quarter of 2025 driven by distributor-restocking after a prolonged period of
backorders. Gross margin was 34% in the second quarter of 2026, reflecting low manufacturing
volumes and the absorption of expenses previously related to a discontinued development
program as compared to the second quarter of 2025. A one-time $2 million settlement payment
from a former contract manufacturer (CMO) contributed to net income in the second quarter of
2026 and is shown in the operating statement as a reduction to operating expenses.”
“We saw an acceleration of our distributors’ out-the-door volume growth to 28% in the second
quarter of 2026, up from 21% in the first quarter of 2026,” said Bobbi Brockmann, Senior Vice
President of Sales and Marketing. “Our momentum was broad-based, driven by both higher
volumes and price realization across sales territories and products. Tri-Shield
®
remained our
primary growth driver at the producer-level, while we had higher sales of Dual-Force
®
to
distribution this quarter as part of normal stocking activity, and our Functional Feed line
continued to gain traction. We are pleased to report continued increases in our share of U.S.
calves receiving a scour biological, reaching 19% this quarter.”
“The 34% gross margin in the second quarter of 2026 was the result of several headwinds in
manufacturing, primarily lower manufacturing volumes as compared to recent quarters, scrap
caused by a quality issue with a purchased material, and the shift of costs formerly associated
with Re-Tain
®
,” explained Mr. Fiori. “The lower output this quarter was aligned with lower sales
volumes, as we were able to meet demand and expand finished goods inventory. Additionally,
we made process changes in our manufacturing process to increase yields in future quarters.”
ImmuCell recently announced the start of a capacity expansion investment to build its scalable
manufacturing capability and ensure continued reliable supply of First Defense
®
using facilities
and equipment associated with the discontinued Re-Tain
®
development program. “We
previously announced an approximately $3.5 million investment in freeze-drying capacity that
we expect to complete in the first half of 2027,” said Mr. Fiori. “ In a second phase, we plan to
invest approximately $4.5 million in our First Defense
®
colostrum liquid processing capacity to
keep pace with demand. This phase is expected to take approximately six additional months.
Currently, we intend to finance these expansions with cash on hand and cash from operations.”
“Our strong commercial results reflect the benefits of restored product availability, investments
in our commercial team and product portfolio, and a favorable domestic calf market,” said
Olivier te Boekhorst, President and CEO. “ We have been highly focused on ensuring reliable
product supply and we are now well-positioned to meet customer demand while we execute a
major capacity expansion program. Over the next 18 months, we expect to triple our capacity
and improve long-term product economics. With greater confidence in our ability to meet
customer demand, we are now prioritizing product cost improvements and strengthening
colostrum sourcing capabilities to support scalable growth.”
Certain Financial Results:
• Second quarter 2026 product sales increased 11.5%, to approximately $7.2 million,
compared to the quarter ended June 30, 2025.
• Second quarter 2026 gross margin declined to 33.9% of product sales compared to 43.7%
during the quarter ended June 30, 2025.
• Net income was $1.8 million, or $0.20 per diluted share, during the quarter ended June
30, 2026 compared to a net income of $0.5 million, or $0.06 per basic share, during the
quarter ended June 30, 2025.
• Adjusted EBITDA (calculation methodology shown below) was $2.7 million in the three
months ended June 30, 2026, as compared to $1.4 million in the three months ended June
30, 2025.
• During the three-month period ended June 30, 2026, ImmuCell received a legal
settlement payment of $2 million from our former Re-Tain
®
contract manufacturer,
which contributed to reported net income and adjusted EBITDA.
Balance Sheet Data as of June 30, 2026:
• Cash and cash equivalents increased to $8.9 million as of June 30, 2026, from $3.8
million as of December 31, 2025, such increase benefiting in part from the $2 million
settlement payment.
• Net working capital increased to approximately $16.6 million as of June 30, 2026 from
$13.0 million as of December 31, 2025.
• Stockholders’ equity increased to $31.4 million as of June 30, 2026 from $27.1 million as
of December 31, 2025.
Non-GAAP Financial Measures: Generally, a non-GAAP financial measure is a numerical
measure of a company’s performance, financial position or cash flow that either excludes or
includes amounts that are not normally included in or excluded from the most directly
comparable measure calculated and presented in accordance with GAAP. The non-GAAP
Three Months Ended June 30,Six Months Ended June 30,
(In thousands, except per share amounts)2026202520262025
Product sales$7,186$6,445$17,543$14,512
Costs of goods sold4,7493,62710,4498,340
Gross profit2,4372,8187,0946,172
Sa les, ma rketi ng a nd a dmi ni stra ti ve expenses2,3821,4164,7532,896
Product development expenses1208324371,589
Other operating income( 2,000)- ( 2,000)-
Opera ti ng expenses5022,2483,1904,485
NET OPERATING INCOME1,9355703,9041,687
Other (expenses) i ncome, net( 54)( 66)( 70)266
I N COME BEFORE I N COME T AX ES1,8815043,8341,953
Income ta x expense462584
NET INCOME$1,835$502$3,776$1,949
Ba si c wei ghted a vera ge common sha res outsta ndi ng9,0659,0319,0559,006
Ba si c net i ncome per sha re$0.20$0.06$0.42$0.22
Di luted wei ghted a vera ge common sha res outsta ndi ng9,1899,0319,1279,006
Di luted net i ncome per sha re$0.20$0.06$0.41$0.22
Condensed Statements of Income (Unaudited)
As ofAs of
J u n e 30, 2026D
ecemb er 31, 2025
Cash and cash equivalents$8,860$3,807
Inventory$9,078$9,267
Net wo rki n g ca pi ta l$16,644$12,967
Total assets$46,630$42,532
Stockholders' equity$31,375$27,055
Selected Balance Sheet Data (In thousands) (Unaudited)
Six Months Ended June 30,
20262025
Operating Activities$6,592$3,175
Investing Activities( 901)( 455)
Financing Activities( 638)( 480)
Net Change in Cash5,0532,
240
Cash at Beginning of Period3,8073,758
Cash at End of Period$8,860$5,998
Selected Cash Flow Data (In thousands) (Unaudited)
measures included in this press release should be considered in addition to, and not as a
substitute for or superior to, the comparable measure prepared in accordance with GAAP.
We believe that considering the non-GAAP measure of Earnings Before Interest, Taxes,
Depreciation and Amortization (EBITDA) assists management and investors by looking at our
performance across reporting periods on a consistent basis excluding certain charges from our
reported income before income taxes. We calculate adjusted EBITDA as described in the
following table and reconciled to the most comparable GAAP financial measure:
During the six-month period ended June 30 2026, we received a legal settlement payment of $2
million from our former Re-Tain
®
CMO, which is part of reported net income and also adjusted
EBITDA. Cash payments to satisfy debt repayment obligations and to make capital expenditure
investments are other uses of cash that are not included in the calculation of EBITDA, but which
management also does consider when assessing its cash flows.
First Defense
®
Capacity Expansion:
In late December 2025 and early January 2026, we announced our plan to convert the former Re-
Tain
®
facilities and most of the related equipment for increased production of our First Defense
®
product line. In June 2026, our Board of Directors authorized a manufacturing capacity
expansion program to execute that strategy.
The first phase expands drying capacity by renovating the former Re-Tain
®
facility and adding a
new freeze dryer with greater capacity and reliability than our current freeze-drying equipment.
This phase is expected to take approximately 12 months and cost approximately $3.5 million. In
a second phase, we plan to repurpose Re-Tain
®
equipment and add additional equipment and
automation to expand our First Defense
®
colostrum liquid processing capacity. The second phase
will involve additional investments, including for detailed engineering work to develop an
efficient and scalable process. This phase is expected to take approximately six months and cost
approximately $4.5 million.
The goal of these capacity expansion investments is to further strengthen our ability to reliably
manufacture First Defense
®
products to meet expected customer demand.
Three Months Ended June 30,Six Months Ended June 30,
(In thousands)2026202520262025
Net income$1,835$502$3,776$1,949
Income tax expense462584
Interest expense (excluding debt issuance and debt discount costs)
92114189231
Depreci a ti on4716639991,335
Amortization (including debt issuance and debt discount costs)
316731
Stock-based compensation expense24067378119
Adjusted EBITDA$2,687$1,364$5,407$3,669
Webcast / Conference Call:
The Company will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to
review the unaudited financial results for the quarter ended June 30, 2026. Interested parties may
access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499
(international).
The live webcast can be accessed at: https://app.webinar.net/EQx8PqBGe36
The live webcast will feature a set of accompanying presentation slides that will subsequently be
available in the Investors section of the Company’s website at: https://immucell.com/investors/
A teleconference replay of the conference call will be available through August 21, 2026, by
dialing (855) 669-9658 (toll free) or (412) 317-0088 (international) and utilizing replay access
code #8659150.
A webcast replay will also be available at: https://app.webinar.net/EQx8PqBGe36
About ImmuCell:
ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in
the fast-growing market for calf health solutions. It develops, manufactures and commercializes
the First Defense
®
line of products that provides Immediate Immunity™ through colostrum-
derived, orally delivered antibodies against the principal viral and bacterial causes of scours.
Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal
calves worldwide. Press releases and other information about the Company are available at:
http://www.immucell.com/investors.
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):
This Press Release contains “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be
identified by the fact that they do not relate strictly to historical or current facts and will often
include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”,
“should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and
similar words and expressions. Such statements include, but are not limited to, any forward-
looking statements relating to:
• our business plans, goals and strategies;
• projections of future financial and operational performance, expense ratios and margins;
• future demand for our products, including the First Defense® product line;
• the sequence, duration, costs and goals of our program to repurpose our former Re-
Tain
®
facility and equipment for First Defense
®
production; and cost recoveries on Re-
Tain
®
equipment no longer in service;
• capital expenditures, contractual commitments, and the anticipated sources and uses of
cash to fund them;
and any other statements that are not historical facts. projections about depreciation expense and its
impact on income for book and tax return purposes; and any other statements that are not historical
facts. These statements reflect management’s current expectations as of the date hereof, are based
on management’s estimates, projections, beliefs and assumptions as of such date; and are not
guarantees of future performance. Such statements involve known and unknown risks and
uncertainties that may cause our actual results, performance or achievements to differ materially,
including risks relating to: competition in our markets; customer acceptance and product
performance; alignment between our manufacturing resources and product demand; supply chain
disruptions affecting our operations and our customer and supplier relationships; the commercial
and operational risks of our current and planned expansion of production capacity; difficulties or
delays in development, testing, regulatory approval, production and marketing of our products, and
other risks and uncertainties detailed from time to time in our filings with the Securities and
Exchange Commission (SEC), including our Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q, and Current Reports on Form 8-K. There can be no assurance that the risks or
developments we anticipate will be those that actually affect us. We undertake no obligation to
update any forward-looking statement, whether as a result of new information, future
developments or otherwise.